What we're reading, December 28, 2015: patients fight for Medicaid coverage of expensive hepatitis C treatment, Express Scripts develops programs to protect insurer's from pricey new drugs, and Republicans divided over Medicaid expansion.
Individuals are pushing back at states that are restricting access to curative treatment for hepatitis C, citing cost reasons. Patients in Indiana—one of 34 states where Medicaid refuses to pay for the $95,000 Harvoni unless there’s proof of liver damage—have filed a class action lawsuit to gain access to the pill and ensure Medicaid covers for it, according to a report by the National Public Radio.
By developing optional programs that include newer expensive drugs, Express Scripts is protecting its clients and their budgets from going topsy-turvy, reports AIS Health. With the Hepatitis Cure Value and Cholesterol Care Value Programs in place, the benefit manager is planning to unveil the Oncology Care Value Program and the Inflation Protection Program come January 2016. With an initial focus on prostate cancer, lung cancer, and renal cell carcinoma, patients covered by participating plans will receive “clinically appropriate and cost-effective medication for a specific indication,” according to Express Scripts senior vice president, Clinical, Research & New Solutions, and Chief Innovation Officer Glen Stettin, MD.
Republicans are divided over the Affordable Care Act (ACA), especially when it comes to Medicaid expansion in the states. According to The New York Times, Republican state governors who want to expand the reach of the ACA within their state are facing grief from Republican members in Congress who do not believe the law holds credibility. While Republican governors in Arizona, Arkansas, Indiana, Iowa, Michigan, Nevada, New Jersey, New Mexico, and Ohio, have expanded Medicaid, governors of South Dakota, Tennessee, and Utah are working towards it.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More